Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors

Anticancer Research

Volumn 21, Issue 6 B, 2001, Pages 4243-4252

  Haddad, Ramsi ^a   Lipson, Kenneth E ^a   Webb, Craig P ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Hepatocyte growth factor; Human cancer; Inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; GELDANAMYCIN; NEUTRALIZING ANTIBODY; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SURAMIN;

ANGIOGENESIS; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; DISEASE ASSOCIATION; ENZYME ACTIVATION; HUMAN; METASTASIS; MORPHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT PLANNING;

ANIMALS; HEPATOCYTE GROWTH FACTOR; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 0035573938     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Molecular cloning of a new transforming gene from a chemically transformed human cell line
2. Tpr, a large coiled coil protein whose amino terminus is involved in activation of oncogenic kinases, is localized to the cytoplasmic surface of the nuclear pore complex
3. The human met oncogene is related to the tyrosine kinase oncogenes
4. Sequence of MET protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors
5. Dimerization mediated through a leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase
6. The human met oncogene is a member of the tyrosine kinase family
7. The met oncogene: A new member of the tyrosine kinase family and a marker for cystic fibrosis
8. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product
9. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats
10. An epithelial scatter factor released by embryo fibroblasts
11. Differential tubulogenic and branching morphogenetic activities of growth factors: Implications for epithelial tissue development
12. Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells
13. BMP-2/ALK3 and HGF signal in parallel to regulate renal collecting duct morphogenesis
14. Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells
15. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor
16. Reconstitution of mammary gland development in vitro: Requirement of c- met and c-erbB2 signaling for branching and alveolar morphogenesis
17. Modulation of HGF-induced tubulogenesis and branching by multiple phosphorylation mechanisms
18. Hepatocyte growth factor stimulates extensive development of branching duct-like structures by cloned mammary gland epithelial cells
19. Roles of hepatocyte growth factor/scatter factor and transforming growth factor-beta1 in mammary gland ductal morphogenesis
20. The Met proto-oncogene mesenchymal to epithelial cell conversion
21. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth
22. Transfer of motogenic and invasive response to scatter factor/hepatocyte growth factor by transfection of human MET protooncogene
23. A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis
24. Regulation of spreading and growth of colon cancer cells by hepatocyte growth factor
25. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility
26. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells
27. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells
28. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factormet signalling in human cells concomitant with induction of the urokinase proteolysis network
29. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis
30. Multistep nature of metastatic inefficiency: Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases
31. Regulation of matrix metalloproteinase-2 (MMP-2) by hepatocyte growth factor/scatter factor (HGF/SF) in human glioma cells: HGF/SF enhances MMP-2 expression and activation accompanying up-regulation of membrane type-1 MMP
32. Disruption of epithelial cell-matrix interactions induces apoptosis
33. HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity
34. Scatter factor induces blood vessel formation in vivo
35. Scatter factor (hepatocyte growth factor) is a potent angiogenesis factor in vivo
36. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factormet-urokinase plasminogen activator-plasmin proteolytic network
37. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor
38. Molecular cloning and expression of human hepatocyte growth factor
39. Interactions between scatter factors and their receptors: Hints for therapeutic applications
40. HGF: A multifunctional growth factor controlling cell scattering
41. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor
42. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA
43. Molecular cloning and sequence analysis of the cDNA for a human serine protease reponsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII
44. Activation of hepatocyte growth factor by two homologous proteases, blood-coagulation factor XIIa and hepatocyte growth factor activator
45. Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity
46. Structure-function analysis of hepatocyte growth factor: Identification of variants that lack mitogenic activity yet retain high affinity receptor binding
47. Generation and characterization of a competitive antagonist of human hepatocyte growth factor, HGF/NK1
48. Heparin binding and oligomerization of hepatocyte growth factor/scatter factor isoforms. Heparan sulfate glycosaminoglycan requirement for Met binding and signaling
49. Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2
50. Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity
51. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding
52. In vivo mitogenic action of HGF on lung epithelial cells: Pulmotrophic role in lung regeneration
53. Stimulatory effects of hepatocyte growth factor on normal and neoplastic human bronchial epithelial cells
54. Hepatocyte growth factor induces proliferation and morphogenesis in nonparenchymal epithelial liver cells
55. Angiogenesis in cancer, vascular, rheumatoid and other disease
56. Protein-protein interactions define specificity in signal transduction
57. The tyrosine kinase encoded by the MET protooncogene is activated by autophosphorylation
58. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase
59. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway
60. Signal transduction in c-met mediated motogenesis
61. Hepatocyte growth factor induces activation of Nck and phospholipase C-gamma in lung carcinoma cells
62. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family
63. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis
64. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses
65. Essential role of Gab1 for signaling by the c-Met receptor in vivo
66. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers
67. Met and hepatocyte growth factor/scatter factor expression in human gliomas
68. Scatter factor expression and regulation in human glial tumors
69. Oncogene amplification in human gliomas: A molecular cytogenetic analysis
70. Expression of scatter factor and c-met receptor in benign and malignant breast tissue
71. Scatter factor protein levels in human breast cancers: Clinicopathological and biological correlations
72. Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer
73. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer
74. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer
75. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer
76. Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas
77. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas
78. Activating mutations for the met tyrosine kinase receptor in human cancer
79. The mutationally activated Met receptor mediates motility and metastasis
80. NK1, a natural splice variant of hepatocyte growth factor/scatter factor, is a partial agonist in vivo
81. Disassociation of met-mediated biological responses in vivo: The natural hepatocyte growth factor/scatter factor splice variant NK2 antagonizes growth but facilitates metastasis
82. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor
83. Expression of the c-Met/HGF receptor in human melanocytic neoplasms: Demonstration of the relationship to malignant melanoma tumour progression
84. Met expression and sarcoma tumorigenicity
85. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor
86. Invasiveness and metastasis of NIH 3T3 cells induced by Methepatocyte growth factor/scatter factor autocrine stimulation
87. Scatter factor and hepatocyte growth factor: Activities, properties, and mechanism
88. Tumorigenesis induced by coexpression of human hepatocyte growth factor and the human met protooncogene leads to high levels of expression of the ligand and receptor
89. Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis
90. Signaling pathways in Ras-mediated tumorigenicity and metastasis
91. Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene
92. Geldanamycin selectively destabilizes and conformationally alters mutated p53
93. Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185
94. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association
95. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin
96. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: Essential role for stress proteins in oncogenic transformation
97. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
98. Cherrington: SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
99. Identification of a competitive HGF antagonist encoded by an alternative transcript
100. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor
101. Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor
102. Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells
103. Cooperative interaction between alpha- and beta-chains of hepatocyte growth factor on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses
104. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
105. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth
106. Kringle domains of human angiostatin. Characterization of the antiproliferative activity on endothelial cells
107. Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4
108. Nk4, a new HGF/SF variant, is an antagonist to the influence of HGF/SF on the motility and invasion of colon cancer cells
109. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor
110. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor
111. Intracellular localisation of suramin, an anticancer drug, in human colon adenocarcinoma cells: A study by quantitative autoradiography
112. Autocrine and paracrine motility factors and their involvement in invasiveness in a human oral carcinoma cell line
113. Prostaglandin production in mouse mammary tumour cells confers invasive growth potential by inducing hepatocyte growth factor in stromal fibroblasts
114. Hepatocyte growth factor is a major mediator in heparin-induced angiogenesis
115. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis
116. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells
117. Hepatocyte growth factor is an invasion/migration factor of rat urothelial carcinoma cells in vitro
118. Hepatocyte growth factor and invasion-stimulatory activity are induced in pleural fluid by surgery in lung cancer patients
119. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
120. Tumor cytotoxic activity of HGF-SF
121. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells
122. Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines